Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer

Proteomic techniques are currently used to understand the biology of different human diseases, including studies of the cell signaling pathways implicated in cancer progression, which is important in knowing the roles of different proteins in tumor development. Due to its poor prognosis, proteomic approaches are focused on the identification of new biomarkers for the early diagnosis, prognosis, and targeted treatment of lung cancer. Cytokines are proteins involved in inflammatory processes and have been proposed as lung cancer biomarkers and therapeutic targets because it has been reported that some cytokines play important roles in tumor development, invasion, and metastasis. In this review, we aim to summarize the different proteomic techniques used to discover new lung cancer biomarkers and therapeutic targets. Several cytokines have been identified as important players in lung cancer using these techniques. We underline the most important cytokines that are useful as biomarkers and therapeutic targets. We also summarize some of the therapeutic strategies targeted for these cytokines in lung cancer.

[1]  Ji-shuai Zhang,et al.  Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer , 2013, PloS one.

[2]  N. Rothman,et al.  Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial. , 2011, Cytokine.

[3]  T. Bayer,et al.  Protein signature for non-small cell lung cancer prognosis. , 2014, American journal of cancer research.

[4]  C. Roussos,et al.  VEGF and IL-18 in induced sputum of lung cancer patients. , 2011, Cytokine.

[5]  J. Lehtiö,et al.  Lung cancer proteomics, clinical and technological considerations. , 2010, Journal of proteomics.

[6]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[7]  D. Messmer,et al.  Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) , 2011, Journal of Cancer Research and Clinical Oncology.

[8]  Jiayou Zhang,et al.  IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. , 2010, Cytokine.

[9]  E. Bargagli,et al.  Proteome analysis of bronchoalveolar lavage in lung diseases , 2006, Proteomics.

[10]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[11]  M. Selbach,et al.  SILAC for biomarker discovery , 2015, Proteomics. Clinical applications.

[12]  Yun Chen,et al.  Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[13]  D. Hicklin,et al.  Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[15]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[16]  Shao-En Ong The expanding field of SILAC , 2012, Analytical and Bioanalytical Chemistry.

[17]  L. Raez,et al.  Active immunotherapy for non-small-cell lung cancer: moving toward a reality , 2011, Expert review of anticancer therapy.

[18]  W. Guo,et al.  Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. , 2014, Cancer biomarkers : section A of Disease markers.

[19]  J. Machiels,et al.  A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[20]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[21]  P. Chaurand,et al.  Mass spectrometry-based proteomic profiling of lung cancer. , 2009, Proceedings of the American Thoracic Society.

[22]  Matthias Mann,et al.  Fifteen years of Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC). , 2014, Methods in molecular biology.

[23]  Li-hua Shang,et al.  Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer , 2015, Scientific Reports.

[24]  T. Lan,et al.  Interleukin-10 promoter polymorphism and susceptibility to lung cancer: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.

[25]  S. Takanashi,et al.  Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. , 2005, Internal medicine.

[26]  Baoan Chen,et al.  Siltuximab (CNTO 328): a promising option for human malignancies , 2015, Drug design, development and therapy.

[27]  E. Venkatraman,et al.  Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. , 2006, Chest.

[28]  T. Mekhail,et al.  Interleukin-2 in Cancer Therapy , 2000, BioDrugs.

[29]  T. Geiger,et al.  Super-SILAC: current trends and future perspectives , 2015, Expert review of proteomics.

[30]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[31]  Wan-ying Wu,et al.  Possible target‐related proteins and signal network of bufalin in A549 cells suggested by both iTRAQ‐based and label‐free proteomic analysis , 2016, Proteomics.

[32]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  T. Poussa,et al.  Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival. , 2010, Cytokine.

[34]  C. Libert,et al.  Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation , 2007, Journal of leukocyte biology.

[35]  E. Garon Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. , 2015, Seminars in oncology.

[36]  G. Murray,et al.  The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis , 2011, PloS one.

[37]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[38]  Ruo-Pan Huang,et al.  Cytokines in cancer drug resistance: Cues to new therapeutic strategies. , 2016, Biochimica et biophysica acta.

[39]  N. Altorki,et al.  The Microenvironment of Lung Cancer and Therapeutic Implications. , 2016, Advances in experimental medicine and biology.

[40]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[41]  K. Kiura,et al.  Induction of TNF-α, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells , 2003, Cancer Chemotherapy and Pharmacology.

[42]  L. Paz-Ares,et al.  Proteomic biomarkers in lung cancer , 2013, Clinical and Translational Oncology.

[43]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[44]  V. Ganju,et al.  The Evolution of Therapies in Non-Small Cell Lung Cancer , 2015, Cancers.

[45]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[46]  Ruo-Pan Huang Cytokine protein arrays. , 2004, Methods in molecular biology.

[47]  M. Karamouzis,et al.  A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer , 2010, Cancer Immunology, Immunotherapy.

[48]  G. Catalano,et al.  Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival , 2000, Cancer Immunology, Immunotherapy.

[49]  J. Barbuto,et al.  Functional analysis of cells obtained from bronchoalveolar lavage fluid (BALF) of lung cancer patients. , 2005, Life sciences.

[50]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[51]  Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk , 2012, Molecular Biology Reports.

[52]  G. Strauss,et al.  Use of tumor markers in lung cancer. , 1994, Hematology/oncology clinics of North America.

[53]  R. Abe,et al.  Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model , 2016, Cancer Immunology, Immunotherapy.

[54]  N. Mukaida,et al.  Chemokines in tumor development and progression. , 2012, Experimental cell research.

[55]  Ewa Wójcik,et al.  Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis , 2006, Oncology.

[56]  J. Reichert Antibodies to watch in 2016 , 2016, mAbs.

[57]  J. Tabarkiewicz,et al.  Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[58]  C. Blank,et al.  Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection1 , 2006, The Journal of Immunology.

[59]  D. Porteous,et al.  Sputum proteomics in inflammatory and suppurative respiratory diseases. , 2008, American journal of respiratory and critical care medicine.

[60]  S. Land,et al.  Cytokine and Cytokine Receptor Single-Nucleotide Polymorphisms Predict Risk for Non–Small Cell Lung Cancer among Women , 2009, Cancer Epidemiology Biomarkers & Prevention.

[61]  E. van Marck,et al.  Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer , 2003, International journal of cancer.

[62]  M. Smyth,et al.  Cytokines in cancer immunity and immunotherapy , 2004, Immunological reviews.

[63]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[64]  J. Nakajima,et al.  γδ T cell therapy for the treatment of non-small cell lung cancer. , 2014, Translational lung cancer research.

[65]  N. Senzer,et al.  Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.

[67]  Wen-Wei Hu,et al.  Tumor-associated macrophages in cancers , 2016, Clinical and Translational Oncology.

[68]  G. Mantovani,et al.  Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites , 2000, Journal of Molecular Medicine.

[69]  Shu-hong Sheng,et al.  Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy , 2014, Clinical and Translational Oncology.

[70]  P. Indovina,et al.  Lung Cancer Proteomics: Recent Advances in Biomarker Discovery , 2011, International journal of proteomics.

[71]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[72]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[73]  H. Groen,et al.  Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. , 1994, Blood.

[74]  Lei Zhang,et al.  Proteomic Analysis of Human Saliva From Lung Cancer Patients Using Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.

[75]  A. Tarhini,et al.  Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. , 2015, Seminars in oncology.

[76]  G. Giaccone,et al.  A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. , 2015, European journal of cancer.

[77]  M. Tagawa,et al.  Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer , 2004, Cancer Immunology, Immunotherapy.

[78]  C. Harris,et al.  Radical causes of cancer , 2003, Nature Reviews Cancer.

[79]  E. Szabo,et al.  Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. , 2009, Journal of the National Cancer Institute.

[80]  Donald Kennedy,et al.  Breakthrough of the Year , 2007, Science.

[81]  E. Felip,et al.  TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. , 2016, The Lancet. Oncology.

[82]  R. Sun,et al.  Antiapoptotic Activity of Autocrine Interleukin-22 and Therapeutic Effects of Interleukin-22-Small Interfering RNA on Human Lung Cancer Xenografts , 2008, Clinical Cancer Research.

[83]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[84]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[85]  Lixia Huang,et al.  Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. , 2014, Cytokine.

[86]  T. Mak,et al.  Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies , 2009, Nature Medicine.

[87]  R. Ramlau,et al.  A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[88]  Melissa H Wong,et al.  Tumor microenvironment complexity: emerging roles in cancer therapy. , 2012, Cancer research.

[89]  Jun-Xia Cao,et al.  Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer , 2014, PloS one.

[90]  P. Woll,et al.  Interleukin-8/CXCL8 is a growth factor for human lung cancer cells , 2004, British Journal of Cancer.

[91]  David Elashoff,et al.  Development of transcriptomic biomarker signature in human saliva to detect lung cancer , 2012, Cellular and Molecular Life Sciences.

[92]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[93]  T. Mak,et al.  Fighting cancers from within: augmenting tumor immunity with cytokine therapy. , 2010, Trends in pharmacological sciences.

[94]  Wei-Chih Liao,et al.  Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma , 2008, Clinical Cancer Research.

[95]  Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy , 2015, Pharmacotherapy.

[96]  Wei Wang,et al.  Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer in Patients with Solitary Pulmonary Nodules. , 2016, Annals of Clinical and Laboratory Science.

[97]  T. Blankenstein The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.

[98]  M. Buyse,et al.  Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. , 2011, The Lancet. Oncology.

[99]  Haiquan Chen,et al.  Integrative Proteomics and Tissue Microarray Profiling Indicate the Association between Overexpressed Serum Proteins and Non-Small Cell Lung Cancer , 2012, PloS one.

[100]  L. Paz-Ares,et al.  Identification of proteomic signatures associated with lung cancer and COPD. , 2013, Journal of proteomics.

[101]  Yan Chen,et al.  Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer , 2016, Journal of Experimental & Clinical Cancer Research.

[102]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[103]  J. Limacher,et al.  TG4010: A therapeutic vaccine against MUC1 expressing tumors. , 2012, Oncoimmunology.

[104]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[105]  B. Palmer,et al.  Interleukin 37 is a fundamental inhibitor of innate immunity , 2010, Nature Immunology.

[106]  Yoshimasa Tanaka,et al.  γδ T Cell Immunotherapy—A Review , 2015, Pharmaceuticals.

[107]  Peiliang Geng,et al.  Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer. , 2015, International journal of clinical and experimental medicine.

[108]  W. Warren,et al.  Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma , 2000, Cancer Immunology, Immunotherapy.

[109]  Yanju Ma,et al.  Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors , 2015, International journal of molecular medicine.

[110]  K. Kikuchi,et al.  Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. , 2004, Lung cancer.

[111]  X. Zhong,et al.  The Treg/Th17 Paradigm in Lung Cancer , 2014, Journal of immunology research.

[112]  J. Ferlay,et al.  International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. , 2014, Lung cancer.

[113]  Elise C. Kohn,et al.  Proteomics as a Tool for Biomarker Discovery , 2007, Disease markers.

[114]  Stefani N. Thomas,et al.  Advances in mass spectrometry-based clinical biomarker discovery , 2016, Clinical Proteomics.

[115]  G. Giamas,et al.  Strategies in functional proteomics: Unveiling the pathways to precision oncology. , 2016, Cancer letters.

[116]  N. Songür,et al.  Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer , 2004, Tumori.

[117]  Shasha Wei,et al.  Quantitative proteomics using SILAC: Principles, applications, and developments , 2015, Proteomics.

[118]  P. Diot,et al.  Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis , 2016, European Respiratory Journal.

[119]  A. Nicolini,et al.  Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. , 2007, Cancer letters.

[120]  C. McDonald,et al.  Quantitative proteomics of bronchoalveolar lavage fluid in lung adenocarcinoma. , 2015, Cancer genomics & proteomics.

[121]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[122]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[123]  F. Tas,et al.  Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. , 2008, Lung cancer.

[124]  G. Fei,et al.  A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer , 2015, OncoTargets and therapy.

[125]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[126]  Putty-Reddy Sudhir,et al.  Proteomics-Based Analysis of Protein Complexes in Pluripotent Stem Cells and Cancer Biology , 2016, International journal of molecular sciences.

[127]  Chien-Jen Chen,et al.  Circulating interleukin‐6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy , 2013, International journal of cancer.

[128]  M. Moran,et al.  Proteomic profiles of human lung adeno and squamous cell carcinoma using super‐SILAC and label‐free quantification approaches , 2014, Proteomics.

[129]  R. Sallam Proteomics in Cancer Biomarkers Discovery: Challenges and Applications , 2015, Disease markers.

[130]  G. Vartholomatos,et al.  Cytokine effects on cell survival and death of A549 lung carcinoma cells. , 2013, Cytokine.

[131]  K. O'Byrne,et al.  The role of inflammation in the pathogenesis of non-small cell lung cancer. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[132]  K. Jain Role of Proteomics in the Development of Personalized Medicine. , 2016, Advances in protein chemistry and structural biology.

[133]  R. Catarino,et al.  IL-6 polymorphism in non-small cell lung cancer: a prognostic value? , 2015, Tumor Biology.

[134]  Tetsuro Baba,et al.  Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro , 2007, Cancer science.

[135]  G. Elmberger,et al.  A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants , 2010, Proteome Science.

[136]  M. Masuda,et al.  Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. , 2013, Japanese journal of clinical oncology.

[137]  Helen H. W. Chen,et al.  Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion , 2006, Oncogene.

[138]  Leah E. Mechanic,et al.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. , 2011, Journal of the National Cancer Institute.

[139]  F. Santolaria,et al.  Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. , 1999, Cytokine.

[140]  C. Wingren,et al.  Antibody array generation and use. , 2014, Methods in molecular biology.

[141]  Hye-Jin Sung,et al.  Biomarkers for the lung cancer diagnosis and their advances in proteomics. , 2008, BMB reports.